Novo Nordisk shares have fallen sharply. Their new obesity drug, CagriSema, did not meet expectations in trials. This setback affects future sales and market position. Eli Lilly's shares saw a rise. Investors are watching competition in the weight-loss drug market closely. Novo's stock is back to levels seen before Wegovy's success.